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Abstract
Background and aim: Toll-like receptors (TLRs), a key component of innate immunity, have recently been
implicated in the pathogenesis of interstitial lung diseases (ILDs). As the involvement of TLRs has not yet been fully
elucidated, the aim of the current study was to examine the expression of various TLRs in the bronchoalveolar
lavage fluid (BALF) of patients with ILDs.
Patients and Methods: We studied prospectively three groups of patients: (1) one group of 35 patients with
fibrotic disorders, 16 with idiopathic pulmonary fibrosis (IPF) and 19 with fibrotic interstitial pneumonias associated
with collagen tissue disorders (CTD-IPs); (2) one group of 14 patients with pulmonary sarcoidosis; and (3) 11 normal
subjects. We evaluated TLR expression with flow cytometry and mRNA expression with real-time PCR.
Results: An overexpression of TLR-3 mRNA was found in fibrotic disorders (CTD-IPs/IPF) in comparison with
sarcoidosis (mean ± SD, 1.104 ± 1.087 versus 0.038 ± 0.03; P = 0.04). Additionally, TLR-3 mRNA was increased in
CTD-IPs in comparison with IPF (P = 0.001), sarcoidosis (P = 0.002) and controls (P = 0.05). An upregulation in TLR-7
and -9 mRNA expression was detected in IPF (P = 0.05) and sarcoidosis (P = 0.05), respectively, when compared to
controls. A higher percentage of TLR-9-expressing cells was found in BALF of CTD-IPs when compared to IPF
(mean ± SD, 36.7 ± 7.06 versus 14.85 ± 3.82; P = 0.025).
Conclusion: We observed distinct profiles of TLR expression in fibrotic and granulomatous disorders. It is likely that
they could play a key role in the pathogenesis of these diseases and represent future therapeutic targets.
Background
Interstitial lung diseases (ILDs) include a wide spectrum
of disorders, many of which are uncommon and many
of unknown etiology. Pathogenesis of idiopathic and
autoimmune fibrotic lung diseases as well as granuloma-
tous lung disorders still remains an enigma. Repetitive
cycles of epithelial injury, fibroblast activation and
abnormal wound repair are considered main events [1].
Several factors such as genetic and epigenetic abnormal-
ities, infections, cytokines and growth factors, increased
oxidative stress, autoantibodies, environmental expo-
sures and gastroesophageal reflux have been suggested
as possible contributors for the initiation and progres-
sion of ILDs [2,3].
The lungs are constantly exposed to pathogens and
their byproducts and represent a frequent site of infec-
tions. Toll-like receptors (TLRs) are pattern recognition
receptors that play a key role in the innate immunity,
representing the first line of host defense against patho-
gens. TLRs localize to various cellular compartments,
depending on the nature of the ligands they recognize.
Thus, TLRs involved in recognition of lipid and protein
ligands are expressed on the plasma membrane (TLR-1,
TLR-2, TLR-4, TLR-5 and TLR-6), whereas TLRs that
detect viral nucleic acids are localized in endolysosomal
cellular compartments (TLR-3, TLR-7, TLR-8 and
TLR-9). Endosomal TLRs recognize various conserved
pathogen-associated molecular patterns (PAMPs) such
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(TLR-9), as well as endogenous ligands released follow-
ing tissue damage, cell death, oxidative stress and decom-
position of extracellular matrix (ECM) [4-6]. TLR
expression can also be detected in type II alveolar epithe-
lial cells, airway epithelial cells, smooth muscle cells and
fibroblasts [7-10]. TLR activation induces signaling path-
ways leading to the expression of inflammatory mediators
and induction of an immune response able to eliminate
the pathogen successfully. However, should this process
be ineffective, the infectious stimuli persist and provoke a
sustained injury, leading to chronic inflammation and
skewing of the immune response from a Th1 toward a
Th2 cytokine pattern, thus facilitating the development of
fibrosis [11]. This has led to the hypothesis that infectious
diseases could be a cofactor in the pathogenesis of ILDs.
Novel data in this field have underlined the role of
TLR-9 in pulmonary fibrosis as it was shown to be over-
expressed in pulmonary fibroblasts of patients with IPF
[12]. Moreover, bleomycin (BLM)-induced fibrosis may
be mediated by activation of TLR-2 and TLR-2 defi-
ciency, or treatment with a TLR-2 antagonist not only
protects but also reverses BLM-induced fibrosis [13].
Infections have been implicated in the pathogenesis of
sarcoidosis, since DNA from mycobacteria and propio-
nibacteria have been found in sarcoid tissue [14,15].
A higher expression of TLR-2 and -4 has been demon-
strated in peripheral blood monocytes [16], and linkage
analysis has indicated that an unidentified polymorph-
ism of TLR-4 is associated with sarcoidosis [17]. TLRs
are also implicated in the pathogenesis of autoimmune
disorders such as systemic lupus erythematosus [18],
rheumatoid arthritis [19-21], systemic sclerosis [22], der-
matomyositis and Sjögren syndrome [23].
Our aim was to investigate whether dysfunctions of
the immune system at the TLR level could elucidate
these pathogenetic pathways and explain differences in
prognosis between fibrotic and granulomatous disorders.
Toward this purpose, we assessed the percentage of
TLR-expressing cells by flow cytometry (TLR-2, -4 and
-9) and the mRNA expression of various TLRs (-2, -3,
-4, -7, -8 and -9) in the bronchoalveolar lavage fluid
(BALF) of the patient group and healthy controls.
Patients and Methods
Patients
Sixty (60) consecutive patients from the Interstitial Lung
Disease Unit of the Department of Thoracic Medicine,
University Hospital of Heraklion, were enrolled in the
study: 35 patients with fibrotic disorders, 16 with idio-
pathic pulmonary fibrosis (IPF) and 19 with fibrotic
interstitial pneumonias associated with collagen tissue
disorders (CTD-IPs), 14 patients with sarcoidosis and 11
control subjects.
The ethics committee of our hospital approved the
protocol, and all patients and controls gave their
consent.
Group A: Fibrotic Lung Disorders
1. IPF: The diagnosis was based on internationally
accepted clinical and imaging criteria [24]. In six cases,
diagnosis was made by video-assisted thoracoscopic sur-
gery (VATS), where the histologic diagnosis of usual
interstitial pneumonia (UIP) was obtained. In the
remaining 10 cases, the diagnosis was made on the basis
of clinical and high-resolution computed tomography
(HRCT) criteria: (1) bilateral basal or widespread
crackles; (2) restrictive ventilatory defect or isolated
reduction of DLCO; (3) computed tomography (CT)
findings indicative of IPF, i.e., predominantly basal and
subpleural microcystic or macrocystic honeycombing,
with variably extensive ground-glass and reticular
abnormalities but no consolidation, nodular abnormal-
ities, or other parenchymal abnormalities (apart from
centrilobular emphysema); and (4) no history of envir-
onmental exposure to a fibrogenic agent or connective
tissue disease [24]. According to the aforementioned cri-
teria, any known cause of pulmonary fibrosis, such as a
connective tissue disorder, was excluded by both immu-
nologic screening and rheumatological clinical
evaluation.
2. CTD-IPs: The diagnosis was based on clinical and
HRCT criteria in accordance with the international
societies’ guidelines [25-27]. In detail, the following
patients were studied (1) eight patients with Rheumatoid
Arthritis (RA) and HRCT characteristics of UIP; (2)
seven patients with systemic sclerosis (SSc) and HRCT
appearance of NSIP; (3) two patients with systemic
lupus erythematous (SLE), one with HRCT features of
NSIP and one with HRCT features of UIP; (4) one
patient with Sjögren syndrome and histologically proven
fibrotic NSIP; and (5) one patient with dermatomyositis-
polymyositis and HRCT features of NSIP.
Group B: Sarcoidosis
Fourteen sarcoidosis patients were enrolled in the study.
Diagnosis was made according to the ATS/ERS/World
Association of Sarcoidosis and Other Granulomatous
Disorders joint statement [28]. All patients had trans-
bronchial or surgical lung biopsy with histopathological
evidence of noncaseating epithelioid cell granulomas
without evidence of infection or inorganic material to
account for the pulmonary granulomatous reaction.
According to the chest radiographic classification of sar-
coidosis, three patients had stage I disease (lymphadeno-
pathy alone), five had stage II disease (lymphadenopathy
and parenchymal opacities) and six had stage III disease
(only parenchymal opacities).
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Pulmonary function tests
All patients were evaluated with complete pulmonary
function tests (PFTs), including spirometry, measure-
ment of lung volumes and diffusion capacity. Spirome-
try, lung volumes using the helium-dilution technique
and TL, CO (corrected for hemoglobin) using the single-
breath technique were performed using a computerized
system (Jaeger 2.12; MasterLab, Würzburg, Germany).
Predicted values were obtained from the standardized
lung function testing of the European Coal and Steel
Community, Luxembourg (1993).
BALF processing
BALF was obtained from all patients as previously
described [29]. Briefly, a flexible bronchoscope was
wedged into a subsegmental bronchus of a predeter-
mined region of interest based on radiographic findings.
A BALF technique was performed by instilling a total of
240 mL of normal saline in 60-mL aliquots, each
retrieved by low suction. The BALF fractions were pooled
and split equally into two samples. One sample was sent
to the clinical microbiology and cytology laboratory, and
the other sample was placed on ice and transported to
the research laboratory. The research sample was filtered
through sterile gauze (Thompson, Ontario, Canada) and
centrifuged at 400 g for 15 min at 4°C.
Total cell counts were determined using an improved
Neubauer counting chamber and expressed as the total
number of cells per millilitre of aspirated fluid. The pellet
was washed three times with cold phosphate-buffered sal-
ine/Dulbecco’s modified Eagle’s medium, and the cells
were adjusted to a final concentration of 10
6 cells/mL with
RPMI 1640 solution plus 2% fetal calf serum. The slide
preparation was performed as previously reported [30].
Flow cytometric analysis
The samples were analyzed on an Epics Elite (Coultronics,
Luton, UK) fluorescence-activated flow cytometer. The
white cells were tightly gated by volume and complexity on
a forward (0{FC33}°) and side light-scattering (90{FC33}°)
mode and by CD45+ expression (pan leukocyte marker).
Am i n i m u mo f1 0
5 cells were analyzed in each case. The
appropriate control was used for subtraction of the back-
ground. The percentage of one- and two- color positive
cells was measured. The following mouse antihuman
monoclonal antibodies were used for labeling BALF cells:
phycocyanate (Pcy-5)-conjugated anti-CD45+, phycoery-
thrin (PE)-conjugated anti-CD3+, fluorescein isothiocya-
nate (FITC)-conjugated anti-CD4+, and FITC-conjugated
anti-CD8+ (Immunotech, Marseille, France). Mouse anti-
mouse isotype-matched FITC-, PE- or PCy-5-conjugated
immunoglobulin were used as control antibodies.
RNA Isolation and Reverse Transcription-Polymerase
Chain Reaction: RNA extraction and reverse transcription
Total RNA was extracted from each specimen using a
power homogenizer and TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. cDNA was synthesized using the Strascript
reverse transcriptase kit (Stratagene, La Jolla, CA, USA)
as previously described [31].
Real-time RT-PCR
TLR mRNA expression was measured using a real-time
RT-PCR assay with SYBR-Green I. Primers were
designed to span introns. b- a c t i nw a su s e da st h ei n t e r -
nal control to normalize TLR-2, TLR-3, TLR-4, TLR-7,
TLR-8 and TLR-9 (Table 1). Specifically, 1 μlc D N A
from all patient and control samples was amplified in a
PCR reaction containing 2 × Brilliant SYBR-Green I
QPCR Master Mix, 300 nM of each primer and 30 μM
ROX passive reference dye in a final volume of 20 μl.
After an initial denaturation at 95°C for 10 min, the
samples were subjected to 40 cycles of amplification
comprising denaturation at 95°C for 30 sec, annealing at
appropriate temperature for each primer pair for 30 sec
and elongation at 72°C for 30 sec, followed by a melt
curve analysis, in which the temperature was increased
from 55°C to 95°C at a linear rate of 0.2°C/sec. Data col-
lection was performed both during annealing and exten-
sion, with two measurements at each step, and at all
times during melt curve analysis. In each PCR reaction
two nontemplate controls were included. All PCR
experiments were conducted on the Mx3000P real-time
PCR thermal cycler using software version 2.00 Build
215, Schema 60 (Stratagene). To verify the results of the
Table 1 Primer sequences used for quantitative
real-time RT-PCR
Gene Primer pair Sequence (5’-3’) Annealing
temperature
TLR-2 For: GGGTTGAAGCACTGGACAAT 55°C
Rev: TTCTTCCTTGGAGAGGCTGA
TLR-3 For: ACACCATCTATTAAAAGACCCATTAT 62°C
Rev: TCCAGATTTTGTTCAATAGCTTGTT
TLR-4 For: GGTCACCTTTTCTTGATTCCA 55°C
Rev: TCAGAGGTCCATCAAACATCAC
TLR-7 For: GCTATCAGATTCAAAAACAACAGAA 55°C
Rev: CACAAACACCTTTGTAGATCACTTCT
TLR-8 For: GGCTTTCTTTCTGAAGTCAGTAGTCT 58°C
Rev: TTTCCGTGTAGTTCCAACATAGATAA
TLR-9 For: CTGAGTGAGAACTTCCTCTACAAATG 58°C
Rev: TCTTTTGGTAATTGAAGGACAGGTTA
b-Actin For: CGGCATCGTCACCAACTG 60°C
Rev: GGCACACGCAGCTCATTG
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electrophoresis in 2% agarose gels stained with ethidium
bromide and photographed on a UV light transillumina-
tor. Primer sequences, annealing temperatures and PCR
products length for all the TLRs analyzed, as well as for
b-actin are shown in Table 1. All reactions were run in
triplicate, and peptide TLR transcript levels were calcu-
lated and normalized to each specimen’s housekeeping
gene mRNA (b-actin) as well as the appropriate calibra-
tors using the ΔΔCt method for relative quantification.
Specifically, after amplification, standard curves were
constructed from samples used in a series of consecutive
dilutions for both the gene of interest and the internal
control (b-actin). TLRs and b-actin amplification effi-
ciencies were the same, reaching 100%. IPF and control
data were first normalized against variation in sample
quality and quantity. Normalized values to b-actin,
ΔCts, were initially calculated using the following equa-
tion: ΔCtsample =C t TLRs -C t b-actin.
Statistical analysis
TLR mRNA levels and flow cytometry results were first
evaluated using the one-sample Kolmogorov-Smirnov
goodness of fit test to determine whether they followed
a normal distribution. On the basis of the results, the
nonparametric Mann-Whitney U test or the parametric
t-test was used to examine correlations. A c
2 test was
used as indicated to examine TLR-2-3-4-7-8-9 expres-
sion status among IPF, sarcoidosis, CTD-IPs and control
groups. Statistical analysis was carried out using SPSS
17.0 software (SPSS, Chicago, IL, USA). Statistical signif-
icance was set at the 95% level (P < 0.05).
Results
Demographics
Patients with fibrotic disorders were older than sarcoi-
dosis patients. Female gender was more prevalent in the
CTD-IPs and sarcoidosis group than in the IPF group.
Most of the patients with CTD-IP were nonsmokers,
whereas most of the patients of all other groups, includ-
i n gc o n t r o l s ,h a dac u r r e n to rp a s ts m o k i n gh i s t o r y .
A trend of significant lower forced vital capacity (FVC)
in IPF in comparison with sarcoidosis patients has been
observed. DLco levels indicated more severe disease in
IPF patients compared to sarcoidosis and healthy con-
trols, while CTD-IP patients had a significantly lower
DLco than sarcoidosis (Table 2).
Flow cytometry results
A statistically significant difference has been found for
TLR-9 expression in BALF cells of patients with CTD-
IPs when compared to IPF patients (mean ± SD, 36.7 ±
7.06 versus 14.85 ± 3.82; P = 0.025) (Figures 1, 2 and
Table 3). Given the heterogeneity of CTD-IP group,
when we compared patients with CTD-IP and HRCT
features of UIP to IPF patients we found that TLR-9
expression was still significantly higher in CTD-UIP
than in IPF (mean ± SD, 34.85 ± 6.92 versus 14.85 ±
3.82; P = 0.05) (Figure 2). No significant difference has
been detected in the flow cytometry results for TLR-2
or TLR-4 among the study groups.
TLR mRNA expression
TLRs mRNA expression was detectable in patients and
control groups as shown in Table 4. TLR-3 mRNA
Table 2 Demographic and lung function characteristics of patient groups
Characteristics Controls IPF CTD-IP SARC P value
Number 11 16 16 14 -
Age* 58.44 ± 3.49 67.27 ± 1.62 64.23 ± 4.29 47.42 ± 4.65 p2:0.001 p3:0.04 p4:0.01
Gender:
(male/female)**
8/3 12/4 3/13 5/9 p1: < 10
-4 p2:0.02
p5:0.002
p6:0.04
Nonsmokers** 3 6 14 5 p1: 0.00 p4:0.004 p5:0.001
Smokers** 7 1 1 4 p3:0.001 p5:0.001
Ex-smokers** 1 9 1 5 p1:0.003 p3:0.02
FEV1* 85.11 ± 7.89 82.44 ± 6.15 86.93 ± 6.37 89.83 ± 6.96 NS
FVC* 91.56 ± 7.46 76.06 ± 5.23 81.07 ± 5.65 91.75 ± 5.97 p2:0.06
FEV1/FVC* 74.56 ± 4.48 85.14 ± 2.76 85.36 ± 2.57 81.36 ± 2.63 p5:0.057
DLCO* 76.22 ± 7.72 54.19 ± 7.18 60.15 ± 5.12 91.3 ± 8.06 p2:0.002 p3:0.05 p4:0.005
KCO* 86.22 ± 8.14 87.63 ± 6.44 79 ± 6.92 108.9 ± 5.91 p2:0.02 p4:0.003 p6:0.04
Values are expressed as means ± SEM (standard error of the mean).
*t-test; P < 0.05 is considered statistically significant.
**c
2 test; P < 0.05 is considered statistically significant.
NS, not significant.
Abbreviations: FEV1: forced expiratory volume in one second, FVC: forced vital capacity, TLC: total lung capacity, DLCO, diffusing capacity for carbon monoxide,
KCO: DLCO per unit lung volume. p1: P value between IPF and CTD-IPs, p2: P value between IPF and sarcoidosis, p3: P value between IPF and control, p4: P value
between CTD-IP and sarcoidosis, p5: P value between CTD-IP and control, p6: P value between sarcoidosis and control.
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fibrotic disorders (CTD-IPs and IPF) when compared
to those with granulomatous disorders (sarcoidosis)
(mean ± SD, 1.104 ± 1,087 versus 0.038 ± 0.037; P =
0.04). In addition, TLR-3 mRNA expression was signif-
icantly higher when we compared patients with CTD-
IP to IPF (mean ± SD, 2.03 ± 2 versus 0.007 ± 0.005;
P = 0.001). When we compared patients with CTD-IP
and HRCT features of UIP to IPF patients, we found
that TLR-3 mRNA expression was still significantly
h i g h e ri nC T D - U I Pt h a ni nI P F( m e a n±S D ,3 . 8 4 7±
3.804 versus 0.007 ± 0.005; P = 0.002). Moreover,
patients with CTD-IP had an increased TLR-3 mRNA
expression in comparison with sarcoidosis (mean ±
SD, 2.03 ± 2 versus 0.038 ± 0.037; P = 0.002) and con-
trol subjects (mean ± SD, 2.03 ± 2 versus 0.0014 ±
0.0008; P = 0.05) (Table 5 and Figure 3). Moreover,
TLR-7 mRNA expression was increased in patients
Figure 1 Expression of Toll-like receptor (TLR)-9 in bronchoalveolar lavage fluid (BALF) cells in one representative patient with
idiopathic pulmonary fibrosis (IPF) (right) and one with fibrotic interstitial pneumonias associated with collagen tissue disorders (CTD-
IP) (left).
Figure 2 Expression of TLR-9 in BALF cells of patients with IPF, CTD-IP and CTD-UIP.
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SD, 5.06 ± 4.12 versus 1.5 ± 1.35; P = 0.05) (Table 5).
TLR-9 mRNA expression was marginally increased in
patients with sarcoidosis when compared to healthy
subjects (mean ± SD, 213.52 ± 211.95 versus 0.58 ±
0.53; P = 0.05) (Table 5). No statistically significant
difference has been detected at the mRNA expression
of TLR-2-4-8 among patient groups and control sub-
jects (Table 5).
Furthermore, we explored the impact of smoking in
TLRs mRNA expression. For this reason, we divided the
patients of each group (IPF, CTD-IP, sarcoidosis) into
two subgroups, the first one composed of current and
ex-smokers and the second one composed of nonsmo-
kers. We correlated the expression of TLRs with cigar-
ette smoking. We have not found any significant
difference in TLR expression between these two sub-
groups in our patient groups.
Discussion
To the best of our knowledge, this is the first attempt to
demonstrate that TLRs are implicated in the pathogen-
esis of fibrotic and granulomatous lung disorders, using
BALF, a minimally invasive, useful tool in the everyday
diagnostic workup of interstitial lung diseases.
We observed an overexpression of TLR-3 mRNA in
patients with fibrotic lung disorders (IPF and CTD-IP)
versus patients with nonfibrotic sarcoidosis, suggesting
that different activity of this receptor could be one of
the mechanisms able to explain the skew toward the
Th2 cytokine pattern which characterizes the develop-
ment of fibrosis. Recently, our study group has proposed
distinct angiogenic profiles between IPF and sarcoidosis
as another possible mechanism for the development of
fibrosis [29,32]. A link between TLR activation and
angiogenesis has been observed in patients with Crohn’s
disease, where activation of TLRs located in gut myofi-
broblast results in an increased secretion of CXC che-
mokine ligand 8 (CXCL8), which is a potent
angiogenetic factor implicated in the development of
fibrosis [33,34].
We also detected an overexpression of TLR-3 mRNA
in CTD-IP samples in comparison with IPF. Moreover,
knowing that CTD-IPs are a heterogeneous group of dis-
eases, we compared patients w i t hI P Ft op a t i e n t sw i t h
CTD-IP and radiologic pattern of UIP. We observed
upregulation of TLR-3 activity when the UIP pattern is
associated with CTDs compared with IPF. It is well
known that interstitial pneumonias have a better prog-
nosis when associated with CTDs than in their idiopathic
forms, even when they exhibit the same histopathologic
pattern [35], reflecting probably distinct pathogenetic
pathways. The overexpression of TLR-3 in CTD-IP and
CTD-UIP patients could be implicated in this phenom-
enon. Furthermore, using flow cytometry, TLR-9 was
found to be overexpressed in BALF cells of patients with
CTD-IP as well as CTD-UIP when compared to IPF. We
have recently suggested that an upregulation of angiogen-
esis in CTD-IPs in comparison with IPF could also be a
plausible explanation [36]. Additionally, an overexpres-
sion of TLR-7 mRNA in patients with IPF versus healthy
subjects was shown, enhancing the possible role of TLRs
in the pathogenesis of fibrotic disease.
TLR-3, -7 and -9, all recognizing endosomal ligands,
are implicated in the innate immunity, recognizing viral
derived RNA and DNA, respectively [7]. Viral infections
are thought to represent cofactors in the pathogenesis
of autoimmune and idiopathic lung fibrosis. Epstein-
Barr virus (EBV) has been isolated from lung tissue of
Table 3 Flow cytometry results
IPF CTD-IP Sarcoidosis Controls P value
TLR-2 18.4 ± 13.27 3.12 ± 0.96 3.23 ± 1.31 4.22 ± 1 NS
TLR-4 32.45 ± 5.41 38.52 ± 4.94 28.06 ± 6.34 29.3 ± 8.15 NS
TLR-9 14.85 ± 3.82 36.7 ± 7.06 27 ± 6.72 36.8 ± 10.26 p1:0.025
Values are expressed as the mean ± SEM (standard error of the mean). Mann-
Whitney U test; P < 0.05 is considered statistically significant. NS, not
significant. p1: P value between IPF and CTD-IPs, p2: P value between IPF and
sarcoidosis, p3: P value between IPF and control, p4: P value between CTD-IP
and sarcoidosis, p5: P value between CTD-IP and control, p6: P value between
sarcoidosis and control.
Table 4 Expression profile of TLR mRNA in patient group and control subjects
IPF CTD-IP SARCOIDOSIS CONTROLS P value
TLR-2 100 (16/16) 94.7 (18/19) 100 (14/14) 88.9 (8/9) NS
TLR-3 12.5 (2/16) 78.94 (15/19) 14.3 (2/14) 33.3 (3/9) p1:< 10
-4 p4: < 10
-4
p5:0.01
TLR-4 93.75 (15/16) 89.4 (17/19) 85.7 (12/14) 77.7 (7/9) NS
TLR-7 93.75 (15/16) 94.7 (18/19) 100 (14/14) 77.7 (7/9) NS
TLR-8 100 (16/16) 100 (19/19) 92.9 (13/14) 100 (9/9) NS
TLR-9 100 (16/16) 100 (19/19) 92.9 (13/14) 77.7 (7/9) p3:0.04
p5:0.03
c
2 test; P < 0.05 is considered statistically significant. NS, not significant. p1: P value between IPF and CTD-IPs, p2: P value between IPF and sarcoidosis, p3: P
value between IPF and control, p4: P value between CTD-IP and sarcoidosis, p5: P value between CTD-IP and control, p6: P value between sarcoidosis and
control.
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[37] and serum complement fixation titers of cytomega-
lovirus (CMV) were elevated in IPF and CTD-IPs [38],
whereas human herpes virus-7 and -8 have also been
detected in IPF [39]. Recent data have shown that TLR-
9 is upregulated in IPF [12]; thus it is likely that viral
infections via activation of TLR-9 could have a key role
in the pathogenesis of IPF as well as in the acute exacer-
bation of the disease observed after an infection. On the
other hand, there are no data in the current literature
regarding TLR involvement in the pathogenesis of auto-
immune lung fibrosis. However, it has been demon-
strated that TLRs are involved in the pathogenesis of
CTDs via activation through endogenous ligands
released during infections [40]. TLR-3 and -9 are
expressed in human synovial tissue from RA patients
[19-21] and in peripheral blood cells in active systemic
lupus erythematosus [18]. Our data demonstrate an
increased expression of TLR-3 and -9 in CTD-IPs com-
pared to IPF, suggesting that endosomal TLRs could be
a reliable marker in the differentiation of autoimmune
from idiopathic fibrosis.
We have also tried to find out if cigarette smoking has
some impact on TLR expression. It is of note now that
smoking is involved in the pathogenesis of pulmonary
fibrosis and influences the outcome [41]. Moreover,
smoking and other environmental agents also have a
negative effect on innate immunity and various cancers
[42]. It has been observed that the expression of TLR-2
and -4 in alveolar macrophage of smokers in response
to their ligands is decreased compared to nonsmokers
[43]. Additionally, infants of smoking mothers had a sig-
nificantly attenuated innate TLR-mediated response
compared with infants of nonsmokers in monocytes
[44]. We have not found any difference in TLR expres-
sion when we subdivided the patients of each one of the
patient groups into smokers (former and current) and
nonsmokers.
However, there are some limitations that need to be
addressed. We used BALF to evaluate the activity of
TLRs instead of lung tissue. Lung tissue is not war-
r a n t e df o rt h ed i a g n o s i so fC T D - I P s ,a si td o e sn o ta d d
information regarding the prognosis of the disease [35]
and diagnosis of IPF can be based on imaging findings
Table 5 mRNA expression of TLRs in patient group and control subjects
IPF CTD-IP Sarcoidosis Controls P value
TLR-2 9.75 ± 7.54 4.04 ± 3.53 599.9 ± 597.7 1.72 ± 1.63 NS
TLR-3 0.007 ± 0.005 2.03 ± 2 0.038 ± 0.037 0.0014 ± 0.0008 p1:0.001
p4:0.002
p5:0.05
TLR-4 2.34 ± 1.61 1.35 ± 1.12 20.98 ± 19.3 12.37 ± 12.24 NS
TLR-7 5.06 ± 4.12 12.92 ± 10.25 29 ± 26.81 1.5 ± 1.35 p3:0.05
TLR-8 11.14 ± 7.89 14.5 ± 11.65 679.33 ± 672.34 8.67 ± 8.51 NS
TLR-9 3.1 ± 2.51 1.54 ± 0.94 213.52 ± 211.95 0.58 ± 0.53 p6:0.05
Values are expressed as means ± SEM (standard error of the mean). Mann-Whitney U test; P < 0.05 is considered statistically significant. NS, not significant.
p1: P value between IPF and CTD-IPs, p2: P value between IPF and sarcoidosis, p3: P value between IPF and control, p4: P value between CTD-IP and sarcoidosis,
p5: P value between CTD-IP and control, p6: P value between sarcoidosis and control.
Figure 3 mRNA expression of TLR-3 in patient group and healthy subjects.
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Page 7 of 9alone, with the exception of cases exhibiting unusual
HRCT findings [24].
Conclusion
In conclusion, we have demonstrated that dysfunctions
of the innate immune system at the TLR level could be
implicated in the pathogenesis of fibrotic and granulo-
matous disorders. TLRs could represent a novel thera-
peutic target for these disorders and in particular for the
most devastating form of fibrosis, IPF. However, further
studies are needed to better understand the pathoge-
netic mechanisms of these complicated diseases.
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